Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONCERT: Concurrent vs Sequential Chemoradiotherapy in Breast Cancer
NCT06926543Phase 3Recruiting
- Start
- May 2024
- Primary completion
- May 2031
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer (2 arms). Primary endpoint: Disease Free Survival at 3 years. Started May 2024; status: recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06926543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06926543.